SOLX 790, a glaucoma laser, has received 510(k) clearance from the FDA and can now be used for Titanium:Sapphire laser trabeculoplasty (TLT) in the United States, the laser's manufacturer, SOLX, has announced.
SOLX 790, a glaucoma laser, has received 510(k) clearance from the FDA and can now be used for Titanium:Sapphire laser trabeculoplasty (TLT) in the United States, the laser's manufacturer, SOLX, has announced. The laser had already been licensed for use in the EU and Canada.
A randomized international multicentre trial enrolled more than 180 subjects to compare TLT with argon laser trabeculectomy (ALT) for intraocular pressure (IOP) reduction. Study subjects had primary open angle glaucoma and poorly controlled IOP on maximally tolerated medications and/or prior failed trabeculoplasty.
At the 12 month follow-up visit, subjects in the TLT treatment arm had achieved a mean IOP reduction of 25.8% (6.8±4.7 mmHg), which had been achieved immediately and maintained throughout the study period; ALT-treated subjects experienced an IOP reduction of 22.2% (5.7±4.8 mmHg). The laser was also found not to cause thermal damage to the trabecular meshwork.
As the TLT treatment was found to be equivalent to ALT treatment, FDA approval for the SOLX 790 laser was granted.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.